Xbrane Bioscience
- Company typePrivate
- Founded2008
- HeadquartersStockholm, Sweden
- Headcount51–100
- GTM typeB2B
- OfferingHardware or Manufacturing
Xbrane Bioscience firmographics
Firmographics- Name
- Xbrane Bioscience
- Website
- https://xbrane.com
- Company type
- Private
- Founded year
- 2008
- Operating status
- Acquired
- Headcount range
- 51–100 employees
- Ownership category
- akta.pro rank
Xbrane Bioscience industry classification
Industry- Product category
- Biosimilar Pharmaceuticals
- NAICS
- Biological Product (except Diagnostic) Manufacturing (325414), Research and Development in Biotechnology (except Nanobiotechnology) (541714)
- SIC
- Biological Products, (No Disgnostic Substances) (2836)
- akta.pro primary industry
- Monoclonal Antibody (mAb) Biosimilars (HLAAAHAA)
- akta.pro secondary industries
- Oncology Biosimilars (HLAAAHAG), Monoclonal Antibody (mAb) Biosimilars (HLAIAFAA)
Keywords
Where Xbrane Bioscience is headquartered
LocationHeadquarters
- HQ city
- Stockholm
- HQ country
- Sweden
- HQ region
- Europe
Markets served
Xbrane Bioscience business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Technology or R&D, Personnel, Operations, Supply Chain
Xbrane Bioscience product offering
Product offeringCore offering
Xbrane Bioscience is a biopharmaceutical company that develops biosimilars, principally an Opdivo (nivolumab) biosimilar candidate intended for regulatory approval and commercialization. Its offering is underpinned by proprietary bacterial protein expression technology used to manufacture biosimilar proteins for oncology indications.
Product overview
Xbrane Bioscience was a biopharmaceutical company focused on developing biosimilars. The company developed an Opdivo (nivolumab) biosimilar candidate, which was undergoing clinical trials as of 2025. Xbrane's R&D organization in Sweden was acquired by Alvotech as part of Alvotech's expansion of its global biosimilars footprint.
Differentiator
Problem solved
Functional benefit
Products and services
- Opdivo Biosimilar A biosimilar candidate targeting Opdivo (nivolumab), being developed for potential regulatory approval and commercialization as a more cost-effective alternative to the originator oncology biologic.
Companies that use Xbrane Bioscience
Customer profileIdeal customer profiles1 record
Xbrane Bioscience technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Xbrane Bioscience partnerships and signals
Strategic signalPartnerships
One partnership is on record.
- AlvotechcoreAlvotech acquired Xbrane's R&D organization in Sweden, expanding its global footprint and capabilities in the biosimilars space. This acquisition represents a significant strategic transaction where Xbrane's R&D capabilities were transferred to Alvotech.
Recent moves5 records
Expansion highlights4 records
Xbrane Bioscience competitors and assessment
Company assessmentDirect peers
- Biocon Biologics: India-based biosimilar developer with a broad mAb biosimilar pipeline including oncology assets. Directly comparable business model focused on developing and commercializing biosimilars for global markets.
- Polpharma Biologics: European biosimilar developer with a pipeline of mAb biosimilars including oncology candidates. Comparable as a focused biosimilar company with operations overlapping Xbrane's European base.
- Alvotech: Global biosimilar developer with a portfolio of monoclonal antibody biosimilars and the acquirer of Xbrane's R&D organization. Directly comparable as a pure-play biosimilar company targeting the same class of complex biologics.
- Celltrion: South Korean biopharmaceutical company and pioneer in mAb biosimilars (Remsima/Inflectra). Comparable as a vertically integrated biosimilar developer with strong commercial reach in oncology and immunology biosimilars.
- Coherus Biosciences: U.S.-based biopharmaceutical company commercializing biosimilars and immuno-oncology products. Directly comparable in business model and target therapeutic areas, with active biosimilar pipeline assets.
- Samsung Bioepis: Biosimilar-focused joint venture between Samsung Biologics and Biogen, developing multiple mAb biosimilars including oncology candidates. Closely comparable in scale, technology focus, and pipeline composition.
Broad incumbents
- Sandoz (Novartis): Global leader in generics and biosimilars, spun out from Novartis, with a substantial biosimilar portfolio including oncology mAbs. Comparable as a broad incumbent in the biosimilars market rather than a niche specialist.
- Viatris: Global pharmaceutical company formed from Mylan and Upjohn with a defined biosimilars franchise including oncology assets. Comparable as a broad incumbent commercializing biosimilars across multiple regions.
- Pfizer: Global biopharmaceutical company with a biosimilars portfolio built through the Hospira acquisition. Comparable as a broad incumbent participating in the biosimilars market alongside a much larger innovative drug portfolio.
- Amgen: Major biopharmaceutical company with an established biosimilars division (e.g., Amjevita, Mvasi). Comparable as a large incumbent developing and commercializing biosimilars alongside a broader innovative biologics portfolio.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat3 records
Key risks6 records
Key highlights7 records
Customer concentration
Xbrane Bioscience social profiles
Digital presenceXbrane Bioscience financial estimates
Financial estimateRevenue estimate
Valuation estimate
Xbrane Bioscience leadership team
Management profileNumber of profiles
Profiles2 records
Xbrane Bioscience funding detail
Funding detailFunding overview
Funding rounds2 records
Investors2 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Xbrane Bioscience M&A and investment
M&A and investmentM&A1 record
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Xbrane Bioscience
What does Xbrane Bioscience do?
Xbrane Bioscience is a biopharmaceutical company that develops biosimilars, principally an Opdivo (nivolumab) biosimilar candidate intended for regulatory approval and commercialization. Its offering is underpinned by proprietary bacterial protein expression technology used to manufacture biosimilar proteins for oncology indications.
Is Xbrane Bioscience a public or private company?
Xbrane Bioscience is a private company. It is classified as public and is currently acquired.
When was Xbrane Bioscience founded?
Xbrane Bioscience was founded in 2008. It employs 51 to 100 people.
Where is Xbrane Bioscience based?
Xbrane Bioscience is headquartered in Stockholm, Sweden, in the Europe region.
Who are Xbrane Bioscience's main competitors?
Direct peers on record are Biocon Biologics, Polpharma Biologics, Alvotech, Celltrion, Coherus Biosciences and Samsung Bioepis. Broad incumbents are Sandoz (Novartis), Viatris, Pfizer and Amgen.
Does Xbrane Bioscience have an API?
No public API is recorded for Xbrane Bioscience.
What industry is Xbrane Bioscience in?
Xbrane Bioscience's product category is Biosimilar Pharmaceuticals. Its primary akta.pro industry code is HLAAAHAA, Monoclonal Antibody (mAb) Biosimilars, with a secondary code of HLAAAHAG, Oncology Biosimilars. Its NAICS code is 325414 and its SIC code is 2836.